NCT04139018View on ClinicalTrials.gov

Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 20, 2019

Primary Completion Date

May 20, 2020

Study Completion Date

May 20, 2020

Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
DRUG

Timolol Gel

Timolol nasal gel 0.1% will be prepared with a poloxamer gel (combination of poloxamer 188 and 407; pH adjusted to 4.5-6.5) and 0.5 ml applied to each nostril twice daily. The total daily dose would amount to 2 mg.

DRUG

Placebo Gel

Placebo gel is prepared with poloxamers and no active ingredients.

Trial Locations (1)

63110

Washington University, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT04139018 - Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia | Biotech Hunter | Biotech Hunter